第 1/1 張圖片
圖片庫
第 1/1 張圖片
有類似物品要出售？
Michael A. Santoro Thomas Ethics and the Pharmaceutical (Paperback) (UK IMPORT)
All Tariffs and Duties included - no additional charges
US $79.46
大約HK$ 618.25
狀況：
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
退貨：
30 日退貨. 由買家支付退貨運費，如果你使用 eBay 郵寄標籤，相關費用將從你的退款金額中扣除.
保障：
請參閱物品說明或聯絡賣家以取得詳細資料。閱覽全部詳情查看保障詳情
（不符合「eBay 買家保障方案」資格）
關於物品
物品細節
- 物品狀況
- 全新: 全新，未閱讀過和使用過的書籍，狀況完好，不存在缺頁或內頁受損。 查看所有物品狀況定義會在新視窗或分頁中開啟
- Country of Origin
- GB
- Book Title
- Ethics and the Pharmaceutical Industry
- Title
- Ethics and the Pharmaceutical Industry
- EAN
- 9780521708883
- ISBN
- 9780521708883
- Genre
- Business & Finance
- Topic
- Technology & Engineering
- Release Year
- 2007
- Release Date
- 07/23/2007
關於產品
Product Identifiers
Publisher
Cambridge University Press
ISBN-10
0521708885
ISBN-13
9780521708883
eBay Product ID (ePID)
61624621
Product Key Features
Number of Pages
528 Pages
Language
English
Publication Name
Ethics and the Pharmaceutical Industry
Subject
Business Ethics, Industries / Pharmaceutical & Biotechnology, Pharmacology
Publication Year
2007
Type
Textbook
Subject Area
Business & Economics, Medical
Format
Trade Paperback
Dimensions
Item Height
1.2 in
Item Weight
24 Oz
Item Length
9 in
Item Width
6 in
Additional Product Features
Intended Audience
Scholarly & Professional
Dewey Edition
22
Reviews
"For intelligent debate on the crisis of confidence in Big Pharma, this volume is unsurpassed. Santoro and Gorrie have assembled an impressive array of voices to tackle contentious issues plaguing the industry, from physician professionalism and research integrity to drug pricing, direct-to-consumer advertising, and intellectual property rights. Combining rigorous analysis with provocative proposals for change, this timely volume should be prescribed reading for industry leaders, policy-makers, and citizens alike." -Lynn S. Paine, John G. McLean Professor of Business Administration, Harvard Business School, "Michael Santoro and Thomas Gorrie have compiled a series of essays that provide a fair, balanced, and insightful examination of an increasingly troubled relationship between the pharmaceutical industry and society." -Henry Thomas Stelfox, Journal of the American Medical Association, "Santoro and Gorrieas book tackles one of the most controversial issues affecting our society 'healthcare: an economic commodity or basic human right?' At the heart of this debate is the role of the pharmaceutical industry. The book highlights effectively the opposing forces underlying the tension between the need for financial incentive for drug discovery and the global need for affordable medicines. It succeeds in providing provocative yet balanced perspectives from leaders of industry, government, ethics, business and healthcare. This book is a must read." -Dr. Victor J. Dzau, President and Chief Executive Officer, Duke University Health System and Chancellor for Health Affairs, Duke University Medical Center, "This book provides thoughtful dialogue from diverse viewpoints on some of the most significant issues in health care -- we need this kind of meaningful dialogue to happen more often." - Tommy G. Thompson, Former Secretary of Health and Human Services and Former Governor of Wisconsin, '... Michael Santoro and Thomas Gorrie have compiled a series of essays that provide a fair, balanced and insightful examination of an increasingly troubled relationship between the pharmaceutical industry and society.' Journal of the American Medical Association, "Santoro and Gorrieas book tackles one of the most controversial issues affecting our society 'healthcare: an economic commodity or basic human right?' At the heart of this debate is the role of the pharmaceutical industry. The book highlights effectively the opposing forces underlying the tension between the need for financial incentive for drug discovery and the global need for affordable medicines. It succeeds in providing provocative yet balanced perspectives from leaders of industry, government, ethics, business and healthcare. This book is a must read." - Dr. Victor J. Dzau, President and Chief Executive Officer, Duke University Health System and Chancellor for Health Affairs, Duke University Medical Center, "Santoro, Gorrie and their contributors succeed in assembling a text that presents the key issues of business conduct for multinational pharmaceutical corporations, in a spirit of dialogue and respect for truly diverse perspectives." -William Avery Hudson blog, "Suffice it to say the book has something in it for almost everyone interested in health care, ethics, and pharmaceuticals. You will learn something from some of the authors, while others will likely make you mad. But they all make you think." -Merrill Matthews, Journal of the National Association for Business Economics, "Santoro and Gorrie have woven together a rich collection of perspectives in Ethics and the Pharmaceutical Industry, with contributors ranging from activists and academicians to regulators and representatives from the industry." -Jeremy Sugarman, Johns Hopkins University, The New England Journal of Medicine, "This book provides thoughtful dialogue from diverse viewpoints on some of the most significant issues in health care -- we need this kind of meaningful dialogue to happen more often." -Tommy G. Thompson, Former Secretary of Health and Human Services and Former Governor of Wisconsin, '… Michael Santoro and Thomas Gorrie have compiled a series of essays that provide a fair, balanced and insightful examination of an increasingly troubled relationship between the pharmaceutical industry and society.' Journal of the American Medical Association, "Ethics and the Pharmaceutical Industry is a timely and thoughtful addition to the growing literature on this controversial subject...I highly recommend this collection of essays as a beginning of a pathway for all parties involved in healthcare." -Alan T. Kaell, Pharmacy and Therapeutics, "Santoro, Gorrie and their contributors succeed in assembling a text that presents the key issues of business conduct for multinational pharmaceutical corporations, in a spirit of dialogue and respect for truly diverse perspectives." William Avery Hudson blog
Illustrated
Yes
Dewey Decimal
338.4/76151
Table Of Content
Charting a sustainable path for the 21st century pharmaceutical industry Michael A. Santoro; Part I. Profits, Patients' Rights, and Scientific Progress: The Ethics of Clinical Research Conducted in Private Enterprises: 1. Drug research: between ethical demands and economic constraints Jurgen Drews; 2. Emerging international norms for clinical testing: good clinical trial practice Juhana E. Idanpaan-Heikkila and Sev S. Fluss; 3. The regulatory and ethical challenges of pediatric research M. Dianne Murphy and Sara F. Goldkind; 4. Including children in research: participation or exploitation? Robert M. Nelson; 5. Racial and ethnic inclusiveness in clinical trials Valentine J. Burroughs; 6. The rights of patients to participate in clinical trials Glenna Crooks; 7. How should government regulate stem-cell research? Perspectives of a scientist-legislator The Hon. Rush Holt; Part II. Marketing and the Efficient Utilization of Healthcare Resources: Ethical and Public Policy Challenges: 8. Ethics and prescribing: the clinician's perspective Charles L. Bardes; 9. Direct-to-consumer advertising of prescription drugs: a policy dilemma Meredith B. Rosenthal and Julie M. Donohue; 10. Regulation of prescription drug promotion Thomas Abrams; 11. Off-label communications in marketing prescription drugs Scott D. Danzis; 12. The need for better health information: advancing the informed patient in Europe Don E. Detmer, Peter Singleton and Scott C. Ratzan; 13. Who should get access to which drugs? An ethical template for pharmacy benefits Norman Daniels, James E. Sabin and J. Russell Teagarden; 14. The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals Joel Hay; Part III. Patents, Pricing, and Equal Access: 15. Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities Patricia H. Werhane and Michael Gorman; 16. A future agenda for government-industry relations William Weldon; 17. AIDS activism and the pharmaceutical industry Martin Delaney; 18. The campaign against innovation Sidney Taurel; 19. Third world perspectives on global pharmaceutical access James Thuo Gathii; 20. The promise of vaccines and the influenza shortage of 2004: public and private partnerships Gary R. Noble; Part IV. Charting a Sustainable Path for the 21st Century: 21. Evolving approaches to healthcare challenges Thomas M. Gorrie; 22. Property rights in crisis: managers and rescue Nien-he Hsieh; 23. Blurring the lines: public and private partnerships addressing global health William Foege; 24. Renegotiating the grand bargain: balancing prices, profits, people, and principles Greg Koski.
Synopsis
Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Debates are raging over how the industry can and should be expected to act. In this volume leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, marketing and advertising. . Michael Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School, where he teaches courses on business ethics, public policy, labor and human rights, law, ethical issues in the pharmaceutical industry and China business strategy. As a Research Associate at Harvard Business School, he wrote or co-authored nearly thirty case studies and teaching notes on ethical and legal topics such as global protection of intellectual property, insider trading, the Federal Sentencing Guidelines and Fair Credit Reporting Act. Thomas Gorrie is Corporate Vice President, Government Affairs & Policy, at Johnson & Johnson, with responsiblity for all federal, state and international government affairs and policy. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich, following the receipt of his doctorate at Princeton University. Gorrie has over 30 years of worldwide health care experience and has worked with various Johnson & Johnson companies in research and development, marketing and sales, business development, strategic planning, general management, international, venture capital, and health policy., The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing., Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing., These papers by doctors, scholars, industry executives, and NGO representatives debate ethics in the pharmaceutical industry., Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Debates are raging over how the industry can and should be expected to act. In this volume leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, marketing and advertising. . Michael Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School, where he teaches courses on business ethics, public policy, labor and human rights, law, ethical issues in the pharmaceutical industry and China business strategy. As a Research Associate at Harvard Business School, he wrote or co-authored nearly thirty case studies and teaching notes on ethical and legal topics such as global protection of intellectual property, insider trading, the Federal Sentencing Guidelines and Fair Credit Reporting Act. Thomas Gorrie is Corporate Vice President, Government Affairs & Policy, at Johnson & Johnson, with responsiblity for all federal, state and international government affairs and policy. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich, following the receipt of his doctorate at Princeton University. Gorrie has over 30 years of worldwide health care experience and has worked with various Johnson & Johnson companies inresearch and development, marketing and sales, business development, strategic planning, general management, international, venture capital, and health policy.
LC Classification Number
HD9665.5.E85 2007
賣家提供的物品說明
賣家公司資料
增值稅編號： GB 864154811
賣家信用評價 （809,378）
- _***n (171)- 買家留下的信用評價。過去 6 個月購買已獲認證The "Latin Classics. Volume 2" CD is brand new, as stated in the ad.The disc itself is of good quality. The CD was packaged in a cardboard box, and unfortunately, the jewel case cracked during transportation and delivery, but the seller compensated for this issue by refunding 20% of the order price. The seller always responds to customer messages, which is very nice. The seller is honest and respectable. I am very pleased with the purchase. Thank you very much! I wish the seller all the best!
- s***e (4)- 買家留下的信用評價。過去 6 個月購買已獲認證The item arrived earlier than expected and with easy shipping; It was carefully packaged and arrived in perfect condition. It's a DVD and I have not played it yet but it is brand new and in sealed packaging. It is what I expected and as described. The price included shipping and was very reasonable. Ordering from another country went very smoothly. Lots of shipping communication. No communication with seller was needed. I am very happy with this seller and definitely recommend them.Non Son Degno Di Te (DVD) Efrikian Morandi Morandi Efrikian (UK IMPORT)（#136374854632）
- .***3 (108)- 買家留下的信用評價。過去 1 個月購買已獲認證Another great Rarewaves purchase. Once again, the DVD I ordered came well-packaged, secure, and exactly as described. Shipping time was the usual two weeks which is understandable. I do consider the price to be fair all said and done. Overall, another great transaction. Thank you.
賣家信用評價 （809,378）
- _***n (171)- 買家留下的信用評價。過去 6 個月購買已獲認證The "Latin Classics. Volume 2" CD is brand new, as stated in the ad.The disc itself is of good quality. The CD was packaged in a cardboard box, and unfortunately, the jewel case cracked during transportation and delivery, but the seller compensated for this issue by refunding 20% of the order price. The seller always responds to customer messages, which is very nice. The seller is honest and respectable. I am very pleased with the purchase. Thank you very much! I wish the seller all the best!
- s***e (4)- 買家留下的信用評價。過去 6 個月購買已獲認證The item arrived earlier than expected and with easy shipping; It was carefully packaged and arrived in perfect condition. It's a DVD and I have not played it yet but it is brand new and in sealed packaging. It is what I expected and as described. The price included shipping and was very reasonable. Ordering from another country went very smoothly. Lots of shipping communication. No communication with seller was needed. I am very happy with this seller and definitely recommend them.Non Son Degno Di Te (DVD) Efrikian Morandi Morandi Efrikian (UK IMPORT)（#136374854632）
- .***3 (108)- 買家留下的信用評價。過去 1 個月購買已獲認證Another great Rarewaves purchase. Once again, the DVD I ordered came well-packaged, secure, and exactly as described. Shipping time was the usual two weeks which is understandable. I do consider the price to be fair all said and done. Overall, another great transaction. Thank you.